The MET-FINGER research project published its first paper on 31 January.
Released in the Alzheimer’s Research & Therapy journal, the publication presents the protocol for the innovative MET-FINGER study.
MET-FINGER is the first ever trial that studies the effects of lifestyle interventions combined with pharmacological treatment, metformin, for prevention of cognitive decline.
Conducted across three sites in the UK, Finland, and Sweden, it will include a total of 600 participants. The findings will be key for the development of a new generation of clinical trials that combine lifestyle interventions and medication.
A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol
(Alzheimer’s Research & Therapy, 16, Article number: 23 (2024))
